MAINZ BIOMED N.V.

Mainz Biomed N.V.

Diagnostics & Research • Healthcare • Mainz, Germany • MYNZ (NCM)

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Mainz Biomed Initiates eAArly DETECT 2 Clinical Study to Evaluate Next Generation Colorectal Cancer Test and Advances Pancreatic Cancer Screening Program - Quiver Quantitative
Quiver Quantitative • Jan 5
2 Small-Cap Biotechs That Could Reward Patient Investors - Yahoo Finance
Yahoo Finance • Dec 12
Mainz Biomed (NASDAQ: MYNZ) signs ColoAlert MOU for Peru, Colombia and Ecuador - Stock Titan
Stock Titan • Nov 18
Mainz Biomed B.V. Amends Articles to Boost Share Capital - TipRanks
TipRanks • Nov 26
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire
GlobeNewswire • Aug 4

Other Diagnostics & Research Companies

View All →
THERMO FISHER SCIENTIFIC INC. logo Thermo Fisher Scientific Inc.
$219.82B market cap
DANAHER CORP /DE/ logo Danaher Corp.
$165.14B market cap
IDEXX LABORATORIES INC /DE logo Idexx Laboratories Inc.
$55.08B market cap
AGILENT TECHNOLOGIES, INC. logo Agilent Technologies, Inc.
$39.23B market cap
IQVIA HOLDINGS INC. logo Iqvia Holdings Inc.
$38.49B market cap
Natera, Inc. logo Natera, Inc.
$32.25B market cap

Frequently Asked Questions

Has MAINZ BIOMED N.V. had layoffs?
No layoff events have been recorded for MAINZ BIOMED N.V. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does MAINZ BIOMED N.V. have?
MAINZ BIOMED N.V. has approximately 19 employees.
What industry is MAINZ BIOMED N.V. in?
MAINZ BIOMED N.V. operates in the Diagnostics & Research industry, within the Healthcare sector.
Is MAINZ BIOMED N.V. a publicly traded company?
Yes, MAINZ BIOMED N.V. is publicly traded under the ticker symbol MYNZ on the NCM. The company has a market capitalization of approximately $0.01 billion.
Where is MAINZ BIOMED N.V. headquartered?
MAINZ BIOMED N.V. is headquartered in Mainz, Germany.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.